IL-4 inhibition of IL-1 induced Matrix Metalloproteinase-3 (MMP-3) expression in human fibroblasts involves decreased AP-1 activation via negative crosstalk involving of Jun N-terminal Kinase (JNK)

Experimental Cell Research

Volumn 319, Issue 10, 2013, Pages 1398-1408

  Chambers, Mariah ^a   Kirkpatrick, Garrett ^a   Evans, Michel ^a   Gorski, Grzegorz ^a   Foster, Sara ^a   Borghaei, Ruth C ^a  

^a PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

AP 1; CFos; CJun; Interleukin 1; Interleukin 4; Matrix metalloproteinase

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 4; PROTEIN C FOS; STRESS ACTIVATED PROTEIN KINASE; STROMELYSIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR JUNB;

ARTICLE; BINDING AFFINITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FIBROBLAST CULTURE; GENE MUTATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL CULTURE; HUMAN TISSUE; NEGATIVE FEEDBACK; ONCOGENE C FOS; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84877920474     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.04.010     Document Type: Article

References (50)

1. Honig J., Rordorf-Adam C., Siegmund C., Wiedemann W., Erard F. Increased interleukin-1 beta (IL-1 beta) concentration in gingival tissue from periodontitis patients. J. Periodontal Res 1989, 24:362-367.
2. Stashenko P., Fujiyoshi P., Obernesser M.S., Prostak L., Haffajee A.D., Socransky S.S. Levels of interleukin 1 beta in tissue from sites of active periodontal disease. J. Clin. Periodontol 1991, 18:548-554.
3. Cheung N.T., Dawes P.T., Poulton K.V., Ollier W.E., Taylor D.J., Mattey D.L. High serum levels of pro-matrix metalloproteinase-3 are associated with greater radiographic damage and the presence of the shared epitope in patients with rheumatoid arthritis. J. Rheumatol. 2000, 27:882-887.
4. van den Berg W.B., Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis: evidence of a dominant role for interleukin-I. Baillieres Best Pract. Res. Clin. Rheumatol 1999, 13:577-597.
5. Shapira L., van Dyke T.E., Hart T.C. A localized absence of interleukin-4 triggers periodontal disease activity: a novel hypothesis. Med. Hypotheses 1992, 39:319-322.
6. Ukai T., Mori Y., Onoyama M., Hara Y. Immunohistological study of interferon-gamma- and interleukin-4-bearing cells in human periodontitis gingiva. Arch. Oral Biol 2001, 46:901-908.
7. Yamamoto M., Fujihashi K., Hiroi T., McGhee J.R., Van Dyke T.E., Kiyono H. Molecular and cellular mechanisms for periodontal diseases: role of Th1 and Th2 type cytokines in induction of mucosal inflammation. J. Periodontal Res 1997, 32:115-119.
8. van der Graaff W.L., Prins A.P., Niers T.M., Dijkmans B.A., van Lier R.A. Quantitation of interferon gamma- and interleukin-4-producing T cells in synovial fluid and peripheral blood of arthritis patients. Rheumatology (Oxford) 1999, 38:214-220.
9. Moissec P., Naviliat M., D'Angeac A.D., Sany J., Banchereau J. Low levels of interleukin-4 and high level of transforming growth factor β in rheumatoid arthritis. Arthritis Rheum. 1990, 33:1180-1187.
10. Dolhain R.J., van der Heiden A.N., ter Haar N.T., Breedveld F.C., Miltenberg A.M. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum. 1996, 39:1961-1969.
11. Ejeil A.L., Gaultier F., Igondjo-Tchen S., Senni K., Pellat B., Godeau G., Gogly B. Are cytokines linked to collagen breakdown during periodontal disease progression?. J. Periodontol 2003, 74:196-201.
12. Jorgensen C., Apparailly F., Couret I., Canovas F., Jacquet C., Sany J. Interleukin-4 and interleukin-10 are chondroprotective and decrease mononuclear cell recruitment in human rheumatoid synovium in vivo. Immunology 1998, 93:518-523.
13. Lubberts E., Joosten L.A., van Den Bersselaar L., Helsen M.M., Bakker A.C., van Meurs J.B., Graham F.L., Richards C.D., van Den Berg W.B. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. J. Immunol. 1999, 163:4546-4556.
14. Werkmeister R., Fillies T., Gaertner C., Joos U., Berdel W.E. A clinical phase I/II trial of rhIL-4 applied topically in patients with oral squamous cell carcinomas to assess safety and therapeutic activity. Oncol. Rep. 2005, 13:449-452.
15. Parsons S.L., Watson S.A., Brown P.D., Collins H.M., Steele R.J. Matrix metalloproteinases. Br. J. Surg. 1997, 84:160-166.
16. D. Sbardella, G.F. Fasciglione, M. Gioia, C. Ciaccio, G.R. Tundo, S. Marini, M. Coletta, Human matrix metalloproteinases: an ubiquitarian class of enzymes involved in several pathological processes, Mol. Aspects Med. 33 (2012) 119-208.
17. Knauper V., Wilhelm S.M., Seperack P.K., DeClerck Y.A., Langley K.E., Osthues A., Tschesche H. Direct activation of human neutrophil procollagenase by recombinant stromelysin. Biochem. J. 1993, 295:581-586.
18. Murphy G., Cockett M.I., Stephens P.E., Smith B.J., Docherty A.J. Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem. J. 1987, 248:265-268.
19. Ogata Y., Enghild J.J., Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J. Biol. Chem. 1992, 267:3581-3584.
20. Lijnen H.R., Arza B., Van Hoef B., Collen D., Declerck P.J. Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3). J. Biol. Chem. 2000, 275:37645-37650.
21. Noe V., Fingleton B., Jacobs K., Crawford H.C., Vermeulen S., Steelant W., Bruyneel E., Matrisian L.M., Mareel M. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J. Cell Sci. 2001, 114:111-118.
22. Matsuno H., Yudoh K., Watanabe Y., Nakazawa F., Aono H., Kimura T. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J. Rheumatol. 2001, 28:22-28.
23. Aiba T., Akeno N., Kawane T., Okamoto H., Horiuchi N. Matrix metalloproteinases-1 and -8 and TIMP-1 mRNA levels in normal and diseased human gingivae. Eur. J. Oral Sci. 1996, 104:562-569.
24. Haerian A., Adonogianaki E., Mooney J., Docherty J.P., Kinane D.F. Gingival crevicular stromelysin, collagenase and tissue inhibitor of metalloproteinases levels in healthy and diseased sites. J. Clin. Periodontol. 1995, 22:505-509.
25. Reynolds J.J., Hembry R.M., Meikle M.C. Connective tissue degradation in health and periodontal disease and the roles of matrix metalloproteinases and their natural inhibitors. Adv. Dent. Res. 1994, 8:312-319.
26. Alpagot T., Bell C., Lundergan W., Chambers D.W., Rudin R. Longitudinal evaluation of GCF MMP-3 and TIMP-1 levels as prognostic factors for progression of periodontitis. J. Clin. Periodontol. 2001, 28:353-359.
27. M. Houseman, C. Potter, N. Marshall, R. Lakey, T. Cawston, I. Griffiths, S. Young-Min, J.D. Isaacs, Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up, Arthritis Res. Ther. 14 (2012) R30.
28. Fukuda K., Fujitsu Y., Kumagai N., Nishida T. Inhibition of matrix metalloproteinase-3 synthesis in human conjunctival fibroblasts by interleukin-4 or interleukin-13. Invest. Ophthalmol. Vis. Sci 2006, 47:2857-2864.
29. Prontera C., Crescenzi G., Rotilio D. Inhibition by Interleukin-4 of stromelysin expression in human skin fibroblasts: role of PKC. Exp. Cell Res. 1996, 224:183-188.
30. Shingu M., Miyauchi S., Nagai Y., Yasutake C., Horie K. The role of IL-4 and IL-6 in IL-1-dependent cartilage matrix degradation. Br. J. Rheumatol. 1995, 34:101-106.
31. Nemoto O., Yamada H., Kikuchi T., Shinmei M., Obata K., Sato H., Seiki M., Shimmei M. Suppression of matrix metalloproteinase-3 synthesis by interleukin-4 in human articular chondrocytes. J. Rheumatol. 1997, 24:1774-1779.
32. Borghaei R.C., Rawlings P.L., Mochan E. Interleukin-4 suppression of interleukin-1-induced transcription of collagenase (MMP-1) and stromelysin 1 (MMP-3) in human synovial fibroblasts. Arthritis Rheum. 1998, 41:1398-1406.
33. Jenkins K., Javadi M., Borghaei R.C. Interleukin-4 suppresses interleukin-1-induced expression of matrix metalloproteinase-3 in human gingival fibroblasts. J. Periodontol. 2004, 75:267-275.
34. Stewart D., Javadi M., Chambers M., Gunsolly C., Gorski G., Borghaei R.C. Interleukin-4 inhibition of interleukin-1-induced expression of matrix metalloproteinase-3 (MMP-3) is independent of lipoxygenase and PPARgamma activation in human gingival fibroblasts. BMC Mol. Biol. 2007, 8:12.
35. Hess J., Angel P., Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J. Cell Sci. 2004, 117:5965-5973.
36. Mechta-Grigoriou F., Gerald D., Yaniv M. The mammalian Jun proteins: redundancy and specificity. Oncogene 2001, 20:2378-2389.
37. Clark I.M., Swingler T.E., Sampieri C.L., Edwards D.R. The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem. Cell Biol. 2008, 40:1362-1378.
38. Quinones S., Buttice G., Kurkinen M. Promoter elements in the transcriptional activation of the human stromelysin-1 gene by the inflammatory cytokine, interleukin 1. Biochem. J. 1994, 302:471-477.
39. Jenkins K., Javadi M., Borghaei R.C. Interleukin-4 suppresses IL-1-induced expression of matrix metalloproteinase-3 in human gingival fibroblasts. J. Periodontol. 2004, 75:283-291.
40. Borghaei R.C., Gorski G., Javadi M. NF-kappaB and ZBP-89 regulate MMP-3 expression via a polymorphic site in the promoter. Biochem. Biophys. Res. Commun. 2009, 382:269-273.
41. Borghaei R.C., Rawlings P.L., Javadi M., Woloshin J. NF-kappaB binds to a polymorphic repressor element in the MMP-3 promoter. Biochem. Biophys. Res. Commun. 2004, 316:182-188.
42. Borghaei R.C., Sullivan C., Mochan E. Identification of a cytokine-induced repressor of interleukin-1 stimulated expression of stromelysin 1 (MMP-3). J. Biol. Chem. 1999, 274:2126-2131.
43. Dokter W.H., Esselink M.T., Halie M.R., Vellenga E. Interleukin-4 inhibits the lipopolysaccharide-induced expression of c-jun and c-fos messenger RNA and activator protein-1 binding activity in human monocytes. Blood 1993, 81:337-343.
44. Dokter W.H.A., Koopmans S.B., Vellenga E. Effects of IL-10 and IL-4 on LPS-induced transcription factors (AP-1, NF-IL6, and NF-kappa B) which are involved in IL-6 regulation. Leukemia 1996, 10:1308-1316.
45. Vesely P.W., Staber P.B., Hoefler G., Kenner L. Translational regulation mechanisms of AP-1 proteins. Mutat. Res. 2009, 682:7-12.
46. Whitmarsh A.J., Davis R.J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 1996, 74:589-607.
47. K. Ebisawa, R. Kato, M. Okada, T. Sugimura, M.A. Latif, Y. Hori, Y. Narita, M. Ueda, H. Honda, H. Kagami, Gingival and dermal fibroblasts: their similarities and differences revealed from gene expression, J. Biosci. Bioeng. 111 (2011)255-258.
48. Asahara H., Fujisawa K., Kobata T., Hasunuma T., Maeda T., Asanuma M., Ogawa N., Inoue H., Sumida T., Nishioka K. Direct evidence of high DNA binding activity of transcription factor AP-1 in rheumatoid arthritis synovium. Arthritis Rheum. 1997, 40:912-918.
49. Shiozawa S., Tsumiyama K. Pathogenesis of rheumatoid arthritis and c-Fos/AP-1. Cell Cycle 2009, 8:1539-1543.
50. Q. Meng, Y. Xia, c-Jun, at the crossroad of the signaling network, Protein Cell 2 (2011) 889-898.